Advertisement

Toxic Shock Syndrome

  • Elicia Skelton
  • Anand Swaminathan
Chapter

Abstract

Toxic shock syndrome (TSS) is a toxin-mediated systemic inflammatory response syndrome that is classically triggered by either Staphylococcus aureus or Group A Streptococcus. Diagnostic criteria for TSS vary depending on the causal bacteria though symptoms typically involve hypotension in addition to multiorgan involvement. Making the diagnosis of TSS can be challenging as symptoms tend to be nonspecific and multisystemic. Characteristic skin findings of macular erythroderma and desquamation may be present later in the illness course or may not be present at all.

Early recognition is paramount as TSS is associated with high mortality rates if left untreated. Treatment involves supportive care including aggressive fluid resuscitation and maintenance of adequate mean arterial pressures and the use of broad-spectrum antibiotics. The use of IVIG has not been validated, but studies suggest benefits in morbidity and mortality.

Keywords

Toxic shock syndrome Staphylococcus aureus Group A Streptococcus Exotoxin Macular erythroderma Desquamation 

References

  1. 1.
    Todd J, Fishaut M, Kapral F. Toxic-shock syndrome associated with phage-group-I Staphylococci. Lancet. 1978;312:1116–8.CrossRefGoogle Scholar
  2. 2.
    Centers for Disease Control (CDC). Reduced incidence of menstrual toxic-shock syndrome–United States, 1980–1990. Tech Rep. 1990;25:421–3Google Scholar
  3. 3.
    Broome CV. Epidemiology of toxic shock syndrome in the United States: overview. Rev Infect Dis. 1989;11:S14–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Shands KN, Schmid GP, Dan BB. Toxic-shock syndrome in menstruating women: association with tampon use and Staphylococcus aureus and clinical features in 52 cases. N Engl J Med. 1980;303:1436–42.CrossRefPubMedGoogle Scholar
  5. 5.
    Davis JP, Chesney PJ, Wand PJ. Toxic-shock syndrome: epidemiologic features, recurrence, risk factors, and prevention The New England. J Med. 1980:1429–35.Google Scholar
  6. 6.
    DeVries AS, Lesher L, Schlievert PM, Al E. Staphylococcal toxic shock syndrome 2000–2006: epidemiology, clinical features, and molecular characteristics. PLoS One. 2011;6(8):e22997.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    MacDonald KL, Osterholm MT, Hedberg CW, Al E. Toxic shock syndrome. A newly recognized complication of influenza and influenza-like illness. JAMA. 1987;257:1053–8.CrossRefPubMedGoogle Scholar
  8. 8.
    Cone LA, Woodard DR, Schlievert PM. Clinical and bacteriologic observations of a toxic shock-like syndrome due to Streptococcus pyogenes. N Engl J Med. 1987;317:146–9.CrossRefPubMedGoogle Scholar
  9. 9.
    Perry S, Reid R. Toxic shock syndrome and streptococcal toxic shock syndrome. In: Tintinalli J, Stapczynski J, Ma O, Cline D, Cydulka R, Meckler G, editors. Tintinalli’s Emergency Medicine: a comprehensive study guide. 7th ed. New York: McGraw-Hill Education LLC; 2011. Ch. 145. p. 999–1003.Google Scholar
  10. 10.
    Fernández-Frackelton M. Toxic shock syndrome. In: Hockberger R, Walls RM, Gausche-Hill M, editors. Rosen’s emergency medicine: concepts and clinical practice. 9th ed. Elsevier; 2017. Ch. 121. p. 1593–7.Google Scholar
  11. 11.
    Stevens DL. Invasive group A streptococcus infections clinical infectious disease. Clin Infect Dis. 1992;14:2–11.CrossRefPubMedGoogle Scholar
  12. 12.
    Low Donald E. Toxic shock syndrome. Crit Care Clin. 2013;29:651–75.CrossRefPubMedGoogle Scholar
  13. 13.
    Centers for Disease Control. Toxic Shock Syndrome (Other Than Streptococcal) (TSS) 2011 Case definition. MMWR Tech Rep. 2011. https://wwwn.cdc.gov/nndss/conditions/toxic-shock-syndrome-other-than-streptococcal/case-definition/2011/.
  14. 14.
    Centers for Disease Control: Streptococcal Toxic Shock Syndrome (STSS) (Streptococcus pyogenes) 2010 case definition. MMWR Tech Rep. 2010. https://wwwn.cdc.gov/nndss/conditions/streptococcal-toxic-shock-syndrome/case-definition/2010/.
  15. 15.
    Burnham JP, Kollef MH. Understanding toxic shock syndrome. Intensive Care Med. 2015;41:1707–10.CrossRefPubMedGoogle Scholar
  16. 16.
    Kaul R, McGeer A, Low DE, Green K, Schwartz B. Population-based surveillance for group A streptococcal necrotizing fasciitis: clinical features, prognostic indicators, and microbiologic analysis of seventy-seven cases. Ontario Group A Streptococcal Study. Am J Med. 1997;103:18–24.CrossRefPubMedGoogle Scholar
  17. 17.
    Chesney PJ, Davism JP, Purdy WK, Wand PJ, Chesney RW. Clinical manifestations of toxic shock syndrome. JAMA. 1981;246:741–8.CrossRefPubMedGoogle Scholar
  18. 18.
    John C, Niermann M, Sharon B, Peterson M, Kranz D, Schlievert P. Staphylococcal toxic shock syndrome erythroderma is associated with superantigenicity and hypersensitivity. Clin Infect Dis. 2009;49:1893–6.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Schlievert PM, Kelly JA. Clindamycin-induced suppression of toxic-shock syndrome--associated exotoxin production. J Infect Dis. 1984;149(3):471.CrossRefPubMedGoogle Scholar
  20. 20.
    Kalyan S, Chow AW. Staphylococcal toxic shock syndrome toxin-1 induces the translocation and secretion of high mobility group-1 protein from both activated T cells and monocytes. Mediators Inflamm. 2008;2008:1.CrossRefGoogle Scholar
  21. 21.
    Kaul R, McGeer A, Norrby-Teglund A, Al E. Intravenous immunoglobulin therapy in streptococcal toxic shock syndrome – a comparative observational study. Clin Infect Dis. 1999;28:800–7.CrossRefPubMedGoogle Scholar
  22. 22.
    Barry W, Hudgins L, Donta ST, Pesanti EL. Intravenous immunoglobulin therapy for toxic shock syndrome. JAMA. 1992;267:3315–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Darenberg J, Ihendyane N, Sjölin J, et al. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:333–40.CrossRefPubMedGoogle Scholar
  24. 24.
    Todd J, Ressman M, Caston S, Todd B, Wiesenthal A. Corticosteroid therapy for patients with toxic shock syndrome. JAMA. 1984;252:3399–402.CrossRefPubMedGoogle Scholar
  25. 25.
    Hajjeh RA, Reingold A, Weil A, et al. Toxic shock syndrome in the United States: surveillance update 1979–1996. Emerg Infect Dis. 1999;5:807–10.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Davies H, McGeer A, Schwartz B, et al. Invasive group A streptococcal infections in Ontario. Can N Engl J Med. 1996;335:547–54.CrossRefPubMedGoogle Scholar
  27. 27.
    Stevens DL, Tanner MH, Winship J. Severe group A streptococcal infections associated with a toxic shock- like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321:1–7.CrossRefGoogle Scholar
  28. 28.
    Demers B, Simor A, Vellend H. Severe invasive group A streptococcal infections in Ontario, Canada: 1987–1991. Clin Infect Dis. 1993;16:792–800.CrossRefPubMedGoogle Scholar
  29. 29.
    Sabella C. Toxic shock syndromes. In: Usatine RP, Sabella C, Smith M, Mayeaux EJ, Jr., Chumley HS, Appachi E, editors. The color atlas of pediatrics. New York: McGraw-Hill; http://accesspediatrics.mhmedical.com.ezproxy.med.nyu.edu/content.aspx?bookid=1443&sectionid=79849415. Accessed 24 July 2017.

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Elicia Skelton
    • 1
  • Anand Swaminathan
    • 2
  1. 1.Emergency MedicineBellevue/NYU Emergency DepartmentNew YorkUSA
  2. 2.Emergency MedicineSt. Joseph’s Regional Medical CenterPattersonUSA

Personalised recommendations